Magnesium for Atrial Fibrillation: Myth or Magic? by Kotecha, Dipak
 
 
University of Birmingham
Magnesium for Atrial Fibrillation: Myth or Magic?
Kotecha, Dipak
DOI:
10.1161/CIRCEP.116.004521
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Kotecha, D 2016, 'Magnesium for Atrial Fibrillation: Myth or Magic?', Circulation Arrhythmia and
Electrophysiology, vol. 9, no. 9. https://doi.org/10.1161/CIRCEP.116.004521
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 05/10/2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Title:  Magnesium for Atrial Fibrillation: Myth or Magic? 
 
Running title:  Magnesium for Atrial Fibrillation: Myth or Magic? 
 (49 characters including spaces) 
 
Author:  Dipak Kotecha, MD PhD PCAP MRCP FESC FHEA 
 
Author affiliations:  Institute of Cardiovascular Sciences, University of Birmingham, 
Birmingham, UK; and Monash Centre of Cardiovascular Research and Education in 
Therapeutics, Monash University, Melbourne, Australia. 
 
Correspondence: d.kotecha@bham.ac.uk  
 
Journal subject terms  
Arrhythmia and Electrophysiology: Atrial Fibrillation 
Quality and Outcomes: Health Services 
 
Word count:  927 
 
Key words:  Atrial fibrillation; Magnesium, Cardioversion; Prevention 
 
 
  
Low magnesium levels have been implicated as a risk factor for the development of atrial 
fibrillation.1  However, like many interventions before it, supplementing magnesium levels 
does not necessarily lead to a successful cardioversion or better prevention of AF in high-risk 
groups.  This issue is clinically important in view of the high burden that AF poses, the 
increasing incidence of AF, and the association of AF with adverse long-term clinical 
outcomes.2  Not only is AF prevalent in the general population (approximately 3%, with 
much higher rates in older patients), but also a frequent comorbidity and risk factor in 
patients with a range of cardiovascular conditions, including heart failure and after cardiac 
surgery.3, 4  Identifying practical and effective methods for managing AF is a clinical 
imperative.  
 
The attention on magnesium as a potential anti-arrhythmic agent is founded on a small 
number of physiological assessments in human and animal models.5  Intravenous magnesium 
directly affects myocardial potassium channels, has voltage-dependent and indirect effects on 
calcium and sodium channels, prolongs the PR interval and increases the refractory period of 
antegrade atrioventricular node conduction.6, 7  However, although low serum magnesium 
levels were associated with incident AF in the Atherosclerosis Risk in Communities (ARIC) 
study, dietary levels were not 8, suggesting a causal disconnect.  This was demonstrated in 
another large community cohort where the association of hypomagnesemia with incident AF 
was identified in long-term follow-up, but not present within the first 90 days.9   
 
In this issue of Circulation: Arrhythmia and Electrophysiology, Rajagopalan and colleagues 
add to the growing evidence-base on this issue by performing a randomized, double-blind, 
placebo-controlled trial of intravenous magnesium prior to electrical cardioversion of AF.10  
261 patients were enrolled with normal magnesium levels at baseline (2.1 ± 0.2 mg/dL).  
Their key finding was that one-hour conversion to sinus rhythm was similar in both the 
magnesium-treated patients and the placebo group (86.4% magnesium versus 86.0% 
placebo).  They also found no difference in biphasic energy requirement, or the number of 
shocks needed in a ramping energy protocol. 
Where does this fit in with other studies? Figure 1 displays trials and meta-analyses that have 
randomized patients to magnesium in a range of situations, including treatment of acute AF, 
prevention of AF during cardiac surgery and facilitation of electrical cardioversion.10-14  
Although varying with respect to population and magnesium dosage, they share common 
features of a small sample size, short follow-up and disappointing treatment effect.   
 
It is likely that patient selection is a major issue – AF is not just a single condition, but the 
endpoint of numerous pathologies.15  Future trials, in this and other areas, should target 
patients better in order to optimize the likelihood of demonstrating treatment effects.  Another 
key problem is the length of follow-up.  The possibility of a longer-term benefit of 
magnesium supplementation is unknown from the current literature. 
Sample size is also important – demonstrating the effect of a treatment is challenging when 
immediate success rates are so high.  This study, and others, may actually be underpowered 
when considering the heterogeneity of patients included, particularly with respect to anti-
arrhythmic drug use.  Nonetheless this data, in addition to other studies discussed, would 
suggest that magnesium is not a useful clinical therapy to improve the success rates of 
electrical cardioversion.  Although there are data to support the use of magnesium for 
facilitating pharmacological cardioversion, this is largely based on retrospective analyses in 
patients receiving ibutilide or dofetilide as antiarrhythmic drug therapy.16-18   
 
Magnesium has also been noted as a potential drug for complementing a rate control 
approach.  In meta-analysis of five randomized trials (n=380), patients receiving magnesium 
were three times as likely to reach a heart rate <100 beats/minute compared to placebo, 
mostly with digoxin as background therapy.13  In 199 patients receiving rate control for rapid 
AF (again mostly with digoxin), those randomized to intravenous supplemental magnesium 
were more likely to reach a rate of <100 beats/minute at two hours (relative risk 1.89; 95% CI 
1.38-2.59).19  While these results are encouraging, magnesium has not been widely adopted 
as a rate control strategy, as more effective agents are available for acute ventricular rate 
control, such as beta-blockers, verapamil and diltiazem.2 
 
The authors of this study are congratulated on recognizing the importance of study design and 
choosing to employ a randomized and blinded approach.  Magnesium has shown potential 
benefits in observational studies, and has an inherent physiological association due to its 
effects on membrane potentials and ion transport.  This exemplifies the problems in assigning 
causality and disentangling the issue of confounding in observational studies, which we 
recently highlighted for digoxin use in AF.20  Although observational data are useful for 
determining epidemiological patterns, decision on treatment effects should be restricted to 
randomized controlled trials, where selection and performance biases can be addressed. 
More trials of magnesium are in-process.  Completed but yet to report is a 300-patient study 
in Tunisia randomizing to high or low-dose magnesium infusion, to assess effects on rate and 
rhythm control in emergency department patients with rapid AF (NCT00965874).  Currently 
recruiting is a double-blind placebo-controlled trial in Thailand of 128 patients to assess sinus 
rhythm conversion and rate control over 6 hours (NCT01049464), and a Norwegian single-
blind trial of 218 patients with paroxysmal AF or flutter, with outcomes of cardioversion 
success at 24 hours and also 3-month AF follow-up (NCT01818583). 
 
Further trial data may shed light on whether there is any role for magnesium in improving the 
management of AF patients.  However at present, the available data would suggest that 
magnesium, as an adjunct to electrical cardioversion or for prevention, is more myth than a 
practical, easy (or magical) solution to the growing problem of AF. 
 
  
Figure 1 
 
 
Legend:  Selected studies and meta-analyses of randomized controlled trials of magnesium 
for facilitating cardioversion or preventing AF.10-14  An ‘event’ is a successful cardioversion 
to sinus rhythm, or the absence of AF on follow-up.  AF = atrial fibrillation; CI = confidence 
interval; Mg = magnesium; N = total number of patients; RCT = randomized controlled trial.  
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